KB-1331

Enoblituzumab

45515

Background of Enoblituzumab

B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Enoblituzumab is a humanized IgG1 mAb that targets B7-H3. The manufacturing goal of this agent was to engineer an Fc that enhanced binding to fragment crystallizable (FC) FcγR (CD16A) and decreased binding to FcγR (CD32B) to augment activation and inhibition, respectively, of antibody-dependent cellular cytotoxicity (ADCC).

Specifications

Catalog Number	KB-1331
Antibody Name	Enoblituzumab
Isotype	Human IgG1,kappa
Target	B7H3
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Feustel K, Martin J, Falchook GS. B7-H3 Inhibitors in Oncology Clinical Trials: A Review. J Immunother Precis Oncol. 2024 Feb 5;7(1):53-66.
Powderly J,, Cote G,, Flaherty K,, et al. Interim results of an ongoing phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunother Cancer. 2015;3:O8.